



Sono-Photodynamic Therapy in the Treatment of Glioblastomas Alternative or Traditional Treatment?

Tzerkovsky Dmitry^{1*}, Grachev Yuri², Protopovich Yagor¹, Stupak Diana¹ and Shashkovsky Dennis³

¹Department of Photodynamic Therapy and Hyperthermia, N.N. Alexandrov National Cancer Center, Belarus

²Department of oncology and neurosurgery, N.N. Alexandrov National Cancer Center, Belarus

³Department of oncology and neurosurgery, Vitebsk State Medical University, Belarus

Abstract

In the presented short article the authors consider the method of sono-photodynamic therapy as an effective option for treating patients with recurrent glioblastomas. According to our data, the inclusion of sono-photodynamic therapy in the scheme of combined treatment of glioblastomas, allows to achieve median overall survival of patients in 20.9 months and median survival after recurrence of disease in 9.4 months.

Keywords: Glioblastoma; Sono-photodynamic therapy; Photosensitizer

Introduction

Glioblastoma (GBM) is one of the most aggressive and malignant brain tumors in humans [1]. Traditional methods of treatment of this severe pathology are surgical intervention with adjuvant chemoradiotherapy [2,3]. Despite the obvious achievements of modern medical science, the prognosis for patients with GBM remains unsatisfactory. According to epidemiological studies, the median overall survival from the time of histological verification varies from 12.6 to 14 month and the percentage of patients alive at 2 years increases from 10.4% to 26.5% [4].

Unsatisfactory results of treatment of this severe pathology make it necessary to search for and develop new methods of treatment. The main requirement for them is the improvement of patient survival rates and a positive impact on the quality of life.

One of such methods is Sono-PhotoDynamic Therapy (SPDT). SPDT is a treatment method based on the significant increase of the cytotoxicity of drugs combined with ultrasound and photoirradiation of the tumor tissue. According to numerous studies of sono-photochemical reactions include a direct interaction of excited molecules with the help of ultrasonic radiation, the Photosensitizer (PS) on the substrate and forming transient radicals that react with oxygen. Interaction initiates a complex cascade of free radicals, such as singlet oxygen, hydroxyl radical, hydrogen peroxide and superoxide anion radical, causing the development of oxidative stress syndrome. As a result, SPDT effectively induced glioma-cell apoptosis and necrosis [5]. At the moment, experimental studies devoted to the study of Sono Dynamic Therapy (SDT) and SPDT are conducted in the scientific centers of South Korea, China and Japan. As photosensitizing agents, the authors use photofrin II, hematoporphyrin, radachlorin and 5-aminolevulinic acid [6-10]. All trials devoted to the study of the effectiveness of methods and SDT and SPDT of malignant gliomas are experimental [5].

In our opinion, the main indications for the use of SPDT in clinical neuro-oncology are:

- GBM (grade IV, WHO), primary and recurrence form.
- Anaplastic astrocytoma (grade III, WHO), primary and recurrence form.
- Anaplastic astrocytoma with transformation into GBM.
- Refusal of patients from the use of traditional methods of treatment (systemic chemotherapy, immunotherapy, etc.)

The treatment regimen for treatment of patients with GBM includes:

- Performing the operation in the volume of complete or partial resection of the tumor.

OPEN ACCESS

*Correspondence:

Tzerkovsky Dmitry, Department of photodynamic therapy and hyperthermia, N.N. Alexandrov National Cancer Center, Lesnoy, Belarus, E-mail: tzerkovsky@mail.ru

Received Date: 27 Mar 2018

Accepted Date: 03 Apr 2018

Published Date: 09 Apr 2018

Citation:

Dmitry T, Yuri G, Yagor P, Diana S, Dennis S. Sono-Photodynamic Therapy in the Treatment of Glioblastomas Alternative or Traditional Treatment?. *Cancer Clin.* 2018; 1(1): 1003.

Copyright © 2018 Tzerkovsky Dmitry. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

- Intravenous infusion of PS.
- Local ultrasound irradiation of the postoperative cavity.
- Photoirradiation of the postoperative cavity.

The pilot study included 18 patients with verified recurrence form of GBM. The study was approved by local ethic committee. Patients signed informed consent to procedure in compliance with Helsinki declaration of 1964 (revised 2013).

After the introduction of patients with anesthesia, the removal of the recurrent tumor was performed in the volume of complete or partial resection. After that, intravenous infusion of the chlorine-based PS «Photolon» (RUE «Belmedpreparaty», Republic Belarus; 2 mg/kg) was performed for 30 minutes. After the end of infusion local ultrasonic irradiation was performed at a frequency of 1.04 MHz with intensity of radiation 0.7 W/cm² for 10 minutes. Photoirradiation of the bed and walls of the removed tumors was performed at the exposure doses of 75 mJ/cm²-100 J/cm² for 9-30 minutes. One month after the treatment, the patients received chemotherapy (lomustin 40 mg (orally) and/or carmustin 2 mg (intravenously)).

The complications and adverse reactions of the applied methods of treatment were headache, convulsive syndrome (n=2) and cerebral edema (n=1). According to our own data, the use of SPDT in combined and complex treatment with recurrence forms of GBM allows to achieve a median overall survival of patients in 20.9 months and a median survival after the recurrence of the disease in 9.4 months.

Conclusion

In our opinion, the SPDT can be recommended as an alternative treatment option for patients with a recurrence of GBM. The received results testify to good tolerability and antitumor efficacy of the developed method. At the moment, a randomized controlled trial has been started in our research center aimed at studying the antitumor efficacy of SPDT in patients with primary forms of GBM.

Acknowledgements

The authors are grateful to all patients included in the study and to all staff of the research center providing medical care to patients.

References

1. Cai X, Sughrue ME. Glioblastoma: New therapeutic strategies to address cellular and genomic complexity. *Oncotarget*. 2017;9(10):9540-54.
2. Velazquez ML, Kharboosh RA, Jeanneret S, Ramos CV, Mahato D, Tavaniaepour D, et al. Advances in brain tumor surgery for glioblastoma in adults. *Brain Sci*. 2017;7(12):166.
3. Mann J, Ramakrishna R, Magge R, Wernicke AG. Advances in radiotherapy for glioblastoma. *Front Neurol*. 2017;8:748.
4. Lee CY. Strategies of temozolomide in future glioblastoma treatment. *Oncotargets Ther*. 2017;10:265-70.
5. Istomin Yu, Tzerkovsky D, Grachev Yu, Artsemyeva T, Borichevsky F, Maslakov E, et al. Intraoperative sono-photodynamic therapy with photolon in animal experiments and promising results of phase I clinical study in patients with recurrent malignant gliomas. *J Neuro-Oncol Neurosci*. 2016;1(1):1-9.
6. Jeong EJ, Seo SJ, Ahn YJ, Choi KH, Kim KH, Kim JK. Sonodynamically induced antitumor effects of 5-aminolevulinic acid and fractionated ultrasound irradiation in an orthotopic rat glioma model. *Ultrasound Med Biol*. 2012;38(12):2143-50.
7. Yamaguchi F, Asakura T, Takahashi H, Kitamura T, Teramoto A. Low frequency ultrasonication induced antitumor effect in 5-aminolevulinic acid treated malignant glioma. *J Cancer Ther*. 2013;4(1):170-5.
8. Song D, Yue W, Li Z, Li J, Zhao J, Zhang N. Study of the mechanism of sonodynamic therapy in a rat glioma model. *Oncotargets Ther*. 2014;7:1801-10.
9. Suehiro S, Ohnishi T, Yamashita D, Kohno S, Inoue A, Nishikawa M, et al. Enhancement of antitumor activity by using 5-ALA-mediated sonodynamic therapy to induce apoptosis in malignant gliomas: Significance of high-intensity focused ultrasound on 5-ALA-SDT in a mouse glioma model. *J Neurosurg*. 2018;19:1-13.
10. Li JH, Chen ZQ, Huang Z, zhan QI, Ren FB, liu JY, et al. In vitro study of low intensity ultrasound combined with different doses of PDT: Effects on C6 glioma cells. *Oncol Lett*. 2013;5(2):702-6.